Morgan Stanley lowered the firm’s price target on Akoya Biosciences to $8 from $15 and keeps an Overweight rating on the shares. The firm expects Akoya to deliver an in-line quarter, but is lowering its FY23, FY24 and FY25 estimates based on a more conservative view of the macro backdrop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKYA:
- Akoya Biosciences announces publication on ultrahigh-plex spatial phenotyping
- Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures
- Akoya Biosciences price target lowered to $11 from $14 at Piper Sandler
- Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023
- Akoya Biosciences participates in a conference call with JPMorgan